Bicycle Therapeutics PLC (BCYC) stock
BCYCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 11/3079% below fair value
$3.37−0.08 (-2.32%)
Close on Nov 13, 2026Market cap $236.22MP/E –Yield 0.00%
Bicycle Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Bicycle Therapeutics's operating margin for the twelve months ending Sep 30, 2026 was -189.4%. For fiscal 2025 it was -340.4%, against -595.0% the year before. The highest annual figure on record is -190.6% in fiscal 2019.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -340.4% | +254.6 |
| FY2024 | Dec 31, 2024 | -595.0% | +109.2 |
| FY2023 | Dec 31, 2023 | -704.1% | +102.4 |
| FY2022 | Dec 31, 2022 | -806.6% | −245.6 |
| FY2021 | Dec 31, 2021 | -561.0% | −60.9 |
| FY2020 | Dec 31, 2020 | -500.1% | −309.5 |
| FY2019 | Dec 31, 2019 | -190.6% | +114.2 |
| FY2018 | Dec 31, 2018 | -304.7% | +482.3 |
| FY2017 | Dec 31, 2017 | -787.0% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -39.6% | +519.1 |
| Q2 FY2026 | Jun 30, 2026 | -8673.9% | −5708.1 |
| Q1 FY2026 | Mar 31, 2026 | -7382.4% | −6678.8 |
| Q4 FY2025 | Dec 31, 2025 | -51.5% | +1773.3 |
| Q3 FY2025 | Sep 30, 2025 | -558.6% | +1827.2 |
| Q2 FY2025 | Jun 30, 2025 | -2965.8% | −2467.5 |
| Q1 FY2025 | Mar 31, 2025 | -703.7% | −541.3 |
| Q4 FY2024 | Dec 31, 2024 | -1824.8% | −807.4 |
| Q3 FY2024 | Sep 30, 2024 | -2385.9% | −1436.8 |
| Q2 FY2024 | Jun 30, 2024 | -498.3% | −120.0 |
| Q1 FY2024 | Mar 31, 2024 | -162.4% | +691.4 |
| Q4 FY2023 | Dec 31, 2023 | -1017.4% | −6.0 |
| Q3 FY2023 | Sep 30, 2023 | -949.1% | +29.8 |
| Q2 FY2023 | Jun 30, 2023 | -378.3% | +245.3 |
| Q1 FY2023 | Mar 31, 2023 | -853.8% | −144.4 |
| Q4 FY2022 | Dec 31, 2022 | -1011.3% | −533.4 |
| Q3 FY2022 | Sep 30, 2022 | -978.9% | −649.0 |
| Q2 FY2022 | Jun 30, 2022 | -623.6% | +344.3 |
| Q1 FY2022 | Mar 31, 2022 | -709.4% | +176.9 |
| Q4 FY2021 | Dec 31, 2021 | -478.0% | −34.6 |
| Q3 FY2021 | Sep 30, 2021 | -329.9% | −52.0 |
| Q2 FY2021 | Jun 30, 2021 | -967.9% | −166.9 |
| Q1 FY2021 | Mar 31, 2021 | -886.3% | +145.0 |
| Q4 FY2020 | Dec 31, 2020 | -443.3% | −353.1 |
| Q3 FY2020 | Sep 30, 2020 | -277.9% | +1392.0 |
| Q2 FY2020 | Jun 30, 2020 | -801.0% | −276.1 |
| Q1 FY2020 | Mar 31, 2020 | -1031.3% | −979.7 |
| Q4 FY2019 | Dec 31, 2019 | -90.2% | +623.3 |
| Q3 FY2019 | Sep 30, 2019 | -1669.9% | −1275.0 |
| Q2 FY2019 | Jun 30, 2019 | -524.8% | −226.3 |
| Q1 FY2019 | Mar 31, 2019 | -51.6% | – |
| Q4 FY2018 | Dec 31, 2018 | -713.5% | – |
| Q3 FY2018 | Sep 30, 2018 | -394.8% | – |
| Q2 FY2018 | Jun 30, 2018 | -298.5% | – |
See a number that looks wrong?